Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 18/20 | 0.62 |
| ▸ | ADORA1 | P30542 | 17/20 | 0.62 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3295339 | 0.82 | ADORA2A (0.72) | ADORA2AADORA1ADORA3 | |
| SCHEMBL13389547 | 0.81 | ADORA2A (0.60) | ADORA2AADORA1ADORA3 | |
| SCHEMBL3297785 | 0.81 | ADORA2A (0.60) | ADORA2AADORA1ADORA3 | |
| SCHEMBL3307751 | 0.80 | ADORA2A (0.82) | ADORA2AADORA1ADORA3 | |
| SCHEMBL3302826 | 0.77 | ADORA2A (1.00) | ADORA2AADORA1 | |
| SCHEMBL3298143 | 0.77 | ADORA2A (0.67) | ADORA2AADORA1ADORA3 | |
| SCHEMBL3301311 | 0.76 | ADORA2A (1.00) | ADORA2AADORA1 | |
| SCHEMBL3303639 | 0.76 | ADORA2A (1.00) | ADORA2AADORA1 | |
| SCHEMBL3306497 | 0.76 | ADORA2A (0.82) | ADORA2AADORA1 | |
| SCHEMBL2305928 | 0.75 | ADORA1 (1.00) | ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010045016-A1 | HETEROCYCLYL AND CYCLOALKYL SUBSTITUTED THIENO [2,3-D] PYRIMIDINE AND THEIR USE AS ADENOSINE A2A RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2010-04-22 | — | — | WO | disclosed |
| US-20100093723-A1 | HETEROCYCLYL AND CYCLOALKYL SUBSTITUTED THIENO[2,3 d]PYRIMIDINE AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-04-15 | — | — | US | disclosed |
| US-20100093723-A1 | HETEROCYCLYL AND CYCLOALKYL SUBSTITUTED THIENO[2,3 d]PYRIMIDINE AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093723-A1 | HETEROCYCLYL AND CYCLOALKYL SUBSTITUTED THIENO[2,3 d]PYRIMIDINE AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS | ADORA2A, ADORA3, ADORA2B | ADORA2A 1/4885ADORA1 4/4885ADORA3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.